Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome–positive acute lymphoblastic leukemia
GUO Ye, LIU Tian-Feng, YANG Wen-Yu, et al.
Diagnostic and Therapeutic Center of Children's Blood Disease, Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China.
. Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome–positive acute lymphoblastic leukemia[J]. CJCP, 2015, 17(6): 634-637.
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia[J]. N Engl J Med, 2006, 354(2):166-178.
[2]
Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. N Engl J Med, 2000, 342(14):998- 1006.
[3]
Schultz KR, Bowman WP, Aledo A, et al. Improved early eventfree survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia:a children's oncology group study[J]. J Clin Oncol, 2009, 27(31):5175-5181.
[4]
Schultz KR, Bowman WP, Aledo A, et al. Continuous dosing Imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosomepositive (Ph+) acute lymphoblastic leukemia (ALL) with longer term follow up:Updated Results of Children's Oncology Group (COG)AALL0031[J]. Pediatr Blood Cancer, 2010, 54:788.
[5]
Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia:Children's Oncology Group Study AALL0031[J]. Leukemia, 2014, 28(7):1467-1471.
Common Terminology Criteria for Adverse Events (CTCAE)[S].Version 4.0. Department of Health and Human Services, National Institutes of Health National Cancer Institute, US. 2009.
Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2008, 49(1):19-26.
[11]
Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia:an update of concepts and management recommendations of European Leukemia[J]. Net. J Clin Oncol, 2009, 27(35):6041- 6051.
[12]
Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia[J]. Blood, 2008, 112(4):1005-1012.
[13]
Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib:a report from the children's oncology group phase I consortium[J]. J Clin Oncol, 2011, 29(7):839-844.
[14]
Hunger SP. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia[J]. Hematol Am Soc Hematol Educ Program, 2011, 2011:361-365.
[15]
Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib:a report from the children's oncology group phase I consortium[J]. J Clin Oncol, 2011, 29(7):839-844.
[16]
Jeha S, Coustan-Smith E, Pei D, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Cancer, 2014, 120(10):1514-1519.
[17]
Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation:the potential of real-time quantitative reversetranscription polymerase chain reaction[J]. Br J Haematol, 2003, 120(1):145-153.
[18]
Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy[J]. Blood, 2013, 122(7):1214- 1221.
